Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer

Protocol changes for the Phase III ARCHES and EMBARK trials will deliver results in hormone-sensitive prostate cancer a year and a half earlier than expected. Xtandi may then gain a valuable new indication sooner than anticipated, but generics for competitor Zytiga could launch before then.

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours

Pfizer Inc. and Astellas Pharma Inc. changed the protocols for the Phase III ARCHES and EMBARK clinical trials testing Xtandi in hormone-sensitive prostate cancer (HSPC) so that the studies now will deliver results about a year and a half earlier than expected for a new, potentially valuable indication – but it still may not gain them much ground ahead of generics for Johnson & Johnson's competing Zytiga.

Pfizer and Astellas said on Aug. 22 that they may complete the ARCHES trial, testing the androgen receptor inhibitor Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in metastatic HSPC, in late 2018 versus the prior expectation of April 2020. Morgan Stanley analyst Shinichiro Muraoka said in an Aug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.